Yale Cancer Center ASCO Participation – 2017 Annual Meeting

Clinical Science Symposia

Monday, June 5, 9:45 AM to 11:15 AM
Location: Hall D1
A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer
Daniel P. Petrylak, MD

Monday, June 5, 1:15 PM to 2:45 PM
Location: S102
Getting to the Heart of the Matter for Colorectal Cancer Survivors
Cary P. Gross, MD

Educational Sessions

Friday, June 2; 1:00 PM
Location: Hall D1
Current Status of Biomarkers for Cancer Immunotherapy
Kurt A. Schalper, MD, PhD

Friday, June 2; 2:00 PM
Location: Hall D1
Future Strategies for Personalized Immunotherapy
Roy S. Herbst, MD, PhD

Friday, June 2; 7:00 PM
Location: Regency AB, Hyatt Regency Chicago
Management of HR-Positive Advanced Breast Cancer: Is There A Right Sequence?
Kerin B. Adelson, MD
Implementation of the Oncology Care Model in an Academic Cancer Hospital
Kerin B. Adelson, MD

Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers
Roy S. Herbst, MD and Daniel P. Petrylak, MD

Using Guidelines to Deliver Precision Cancer Care
Anne Chiang, MD

Overview of the Immune System in Plasma Cell Disorders
Madhav V. Dhodapkar, MBBS

Developmental Therapeutics—Clinical Pharmacology/Experimental Therapeutics
Patricia LoRusso, DO

Supportive Care and Decision-Making in Thoracic Oncology in a Time of Therapeutic Enthusiasm
Carolyn Jean Presley, MD

In the Era of Immunotherapy and Targeted Therapies What Is the Most Appropriate Frontline Therapy and Beyond for Widely Metastatic Disease?
Barbara A. Burtness, MD

Oral Abstract Sessions

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
Charles S. Fuchs
Monday, June 5; 8:00 AM to 11:00 AM
Location: S100a
*Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.*
Barbara Burtness

*LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts)*
Barbara Burtness

Monday, June 5; 3:00 PM to 6:00 PM
Location: Hall D2
*Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)*
Howard S. Hochster

*SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer*
Hui Zheng and Charles S. Fuchs

**Poster Discussion Sessions**

Saturday June 3, 1:15 PM to 2:30 PM
Location: Arie Crown Theater
*Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance)*
Charles S. Fuchs

Saturday, June 3; 4:45 PM to 6:00 PM
Location: Hall D2
*A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201*
Barbara Burtness and Howard Hochster

*SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer*
Stacey Stein and Howard Hochster

Location: S404
*I Like to Move It Move It:* Exercise, Fatigue, and Quality of Life
Tara Sanft

Sunday, June 4; 11:30 AM to 12:45 PM
Location: Hall D2
*Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial*
Vasiliki Pelekanou, David L. Rimm and Lajos Pusztai

*Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic*
leukemia: A report from the Children’s Oncology Group (COG) AALL0932
Nina Kadan-Lottick

Monday, June 5; 11:30 AM to 12:45 PM
Location: E354b
A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure
Amer Zeidan

Poster Sessions: Hall A

Saturday, June 3; 8:00 AM to 11:30 AM
A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 for advanced/ metastatic esophageal, gastric, or gastroesophageal junction cancer: SWOG S1201
Barbara Burtness and Howard Hochster

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Stacey Stein and Howard Hochster

Prognostic signatures of oligometastasis in colorectal cancer liver metastasis
Sajid A. Khan

Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations
Maria Toki and David Rimm

SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma
Howard Hochster

Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study
Charles S. Fuchs

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010
Roy S. Herbst

A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C
Roy S. Herbst

Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513
Howard Hochster

Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance)
Charles S. Fuchs

Saturday, June 3; 1:15 PM to 4:45 PM
Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors
Ranjit Bindra, Parker L Sulkowski, Christopher D. Corso, Peter Glazer and Brian M. Shuch

Sunday, June 4; 8:00 AM to 11:30 AM
Microvessel density as a prognostic marker in high-risk renal cell carcinoma
Sarah A. Weiss and Harriet Kluger

Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial
Vasiliki Pelekanou, David L. Rimm and Lajos Pusztai

Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitantly with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial
Lajos Pusztai, Andrea Silber, Erin Wysong Hofstatter, Gina G. Chung, Nina Ruth Horowitz, Donald R. Lannin, Brigid K. Killelea, Anees B. Chagpar, Borbala Szekely, Courtney Frederick, Lawrence Rispoli, Michael DiGiovanna

Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and S-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer
Julia Foldi, Sarah Schellhorn Mougalian, Andrea Silber, Donald R. Lannin, Brigid K. Killelea, Anees B. Chagpar, Nina Ruth Horowitz, Courtney Frederick, Lawrence Rispoli, Maysa M. Abu-Khalaf, Kert D. Sabbath, Tara Beth Sanft, Neal A. Fischbach, Debra S. Brandt, Erin Hofstatter, Michael DiGiovanna and Lajos Pusztai

Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG) AALL0932
Nina Kadan-Lottick

Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC)
Lajos Pusztai

Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy
Yao Wong

Monday, June 5; 8:00 AM to 11:30 AM
Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study
Amer M Zeidan, Xin Hu, Jessica B. Long, Rong Wang, Scott F. Huntington, Nikolai Alexandrovich Podoltsev, Smith Giri, Maximilian Stahl, Steven Gore, Xiaomei Ma and Amy J. Davidoff
Racial disparities in the use of programmed death-1 checkpoint inhibitors
Kerin B. Adelson, Carolyn Jean Presley, Anne C. Chiang, Joseph S. Ross, Cary Philip Gross and Jeremy O'Connor

Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL)
Francine Foss

A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure
Amer Zeidan

A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM)
Madhav Dhodapkar

Monday, June 5th; 1:15 PM to 4:45 PM
Physician volume and discontinuation of rituximab during lymphoma treatment
Scott F. Huntington, Jessica B. Long, Jessica R. Hoag, Rong Wang, Amer M Zeidan, Smith Giri, Steven Gore, Xiaomei Ma, Cary Gross and Amy J. Davidoff

CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis
William S. Chen, Ranjit Bindra, Zain Husain, Joseph N. Contessa, Stephen G. Gaffney, Jeffrey P. Townsend and James B. Yu

Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer
Erin Wysong Hofstatter, Anees Chagpar, Vikram Wali, Veerle Bossuyt and Lajos Pusztai

Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer
Carolyn Jean Presley, Pamela R. Soulos, Anne C. Chiang, Janina A Longtine, Kerin B. Adelson, Roy S. Herbst and Cary Philip Gross

Changes in insurance coverage associated with health care reform for cancer survivors aged 19-64 years
Amy J Davidoff and Xin Hu

Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies
Barbara Burtness